1 |
Aragort De Rossell R, Calcagno M, Rossell 0, Maizo De Segnini Z, Rodriguez AM (2001) Intralesional isotype profiles in human localized cutaneous leishmaniasis lesions. Int J Exp Pathol 82: 129-134
DOI
ScienceOn
|
2 |
Goncalves CC, Reiche EM, De Abreu Filho BA, Silveira TG, Felizardo TC, Maia KR, Costacurta R, Padovesi EJ, Dias Filho BP, Jankevicius SI, Jankevicius JV (2002) Evaluation of antigens from various Leishmania species in a Western blot for diagnosis of American tegumentary leishmaniasis. Am J Trop Med Hyg 66: 91-102
DOI
|
3 |
Gumy A, Louis JA, Launois P (2004) The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in the cell differentiation in mice from different genetic background. Int J Parasitol 34: 433-444
DOI
ScienceOn
|
4 |
Lange UG, Mastroeni P, Blackwell JM, Stober CB (2004) DNA-Salmonella enterica serovar Typhimurium primerbooster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 72: 4924-4928
DOI
ScienceOn
|
5 |
Rafati S, Salmanian AH, Hashemi K, Schaff C, Belli S, Fasel N (2001) Identification of Leishmania major cysteine proteinases as targets of the immune response in humans. Mol Biochem Parasitol 113: 35-43
DOI
ScienceOn
|
6 |
Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, Ovendale PJ, Picha KS, Morrissey PJ, Grabstein KH, Campos-Nero A, Reed SG (1998) LeIF: a recombinant Leishmania protein that induces an IL-12mediated Thl cytokine profile. J Immunol 161: 6171-6179
|
7 |
Tewary P, Sukumaran B, Saxena S, Madhubala R (2004) Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen. Vaccine 22: 3053-3060
DOI
ScienceOn
|
8 |
Carmelo E, Martinez E, Gonzalez AC, Pinero JE, Patarroyo ME, Del Castillo A, Valladares B (2002) Antigenicity of Leishmania braziliensis histone H1 during cutaneous leishmaniasis: localization of antigenic determinants. Clin Diagn Lab Immunol 9: 808-811
DOI
|
9 |
de Oliveira CI, Teixeira MJ, Gomes R, Barral A, Brodskyn C (2004) Animal models for infectious diseases caused by parasites: Leishmaniasis. Drug Discovery Today: Diseases models 1: 81-86
DOI
ScienceOn
|
10 |
Iborra S, Soto M, Carrion J, Alonso C, Requena JM (2004) Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniasis. Vaccine 22: 3865-3876
DOI
ScienceOn
|
11 |
Kelly BL, Locksley RM (2004) The Leishmania major LACK antigen with an immunodominant epitope at amino acids 156 to 173 is not required for early Th2 development in BALB/c mice. Infect Immun 72: 6924-6931
DOI
ScienceOn
|
12 |
Chang KP, Reed SG, McGwire BS, Soong L (2003) Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop 85: 375-390
DOI
ScienceOn
|
13 |
Shimizu Y, Yamakami K, Gomi T, Nakata M, Asanuma H, Tadakuma T, Kojima N (2003) Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorg Med Chem 11: 1191-1195
DOI
ScienceOn
|
14 |
Sacks D, Anderson C (2004) Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol Rev 201: 225-238
DOI
ScienceOn
|
15 |
Afrin F, Anam K, Ali N (2000) Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes. J Parasitol 86: 730-735
DOI
|
16 |
Trujillo C, Ramirez R, Velez ID, Berberich C (1999) The humoral immune response to the kinetoplastid membrane protein-ll in patients with American leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes. Immunol Lett 70: 203-209
DOI
ScienceOn
|
17 |
Brito ME, Mendonca MG, Gomes YM, Jardim ML, Abath FG (2001) Dynamics of the antibody response in patients with therapeutic or spontaneous cure of American cutaneous leishmaniasis. Trans R Soc Trap Med Hyg 95: 203-206
DOI
ScienceOn
|